Inari Medical announced preliminary unaudited fourth quarter and full year 2022 revenue and provided estimates for its 2023 guidance. Preliminary Fourth Quarter Highlights: Preliminary unaudited revenue for the fourth quarter of 2022 is expected to be between $107.0 million and $108.0 million, up 12% sequentially and 29% year-over-year. "Our fourth quarter was successful and highly productive. We executed crisply across all five of our growth drivers and generated robust revenue growth," said Drew Hykes, CEO of Inari Medical. "We presented important new data from both the CLOUT registry and the U.S. arm of our FLASH registry, the largest prospective thrombectomy trials ever conducted in DVT and PE. We also initiated the full market release of two new products while continuing our work to drive market expansion and uptake of our devices. Looking ahead, we remain fully committed to our mission of better outcomes for our patients while continuing to deliver sustained, premium growth."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NARI:
